Those with NASH resolution also experienced a greater decrease in AST (20- vs 14-U/L decrease; P < .001), ALT (33-U/L vs 26-U/L decrease; P < .001), and fasting insulin levels (4.1-μU/mL decrease vs 0.4-μU/mL increase [to convert to picomoles per liter, multiply by 6.945]; P = .05). This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.